Fulgent Genetics, Inc. (FLGT) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $16.02. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is FLGT = $36 (+124.7% upside).
Valuation: FLGT trades at a trailing Price-to-Earnings (P/E) of -7.8 (S&P 500 average ~25).
Financials: revenue is $323M, -13.8%/yr average growth. Net income is $61M (loss), growing at -61.4%/yr. Net profit margin is -18.8% (negative). Gross margin is 40.6% (-18.7 pp trend).
Balance sheet: total debt is $476,000 against $1.1B equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 6.48 (strong liquidity). Debt-to-assets is 0%. Total assets: $1.2B.
Analyst outlook: 6 / 9 analysts rate FLGT as buy (67%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 25/100 (Fail), Health 67/100 (Partial), Moat 42/100 (Fail), Future 73/100 (Pass), Income 10/100 (Fail).
